Publication date: Oct 27, 2024
Hematological malignancies are associated with an increased risk of complications during SARS-CoV-2 infections. Primary series or monovalent booster vaccines reduce disease severity, hospitalization, and death among multiple myeloma patients. We characterized virus-neutralizing and spike-binding antibody profiles following monovalent (WA1) or bivalent (WA1/BA. 5) SARS-CoV-2 booster vaccination in MM patients. Bivalent vaccination improved the breadth of binding antibodies but not neutralization activity against contemporary variants. Hybrid immunity and immune imprinting impact vaccine-elicited immunity.
Open Access PDF
| Concepts | Keywords |
|---|---|
| Hospitalization | Antibodies |
| Monovalent | Binding |
| Myeloma | Bivalent |
| Vaccines | Booster |
| Variants | Cov |
| Divergence | |
| Hybrid | |
| Immunity | |
| Monovalent | |
| Myeloma | |
| Patients | |
| Sars | |
| Vaccination | |
| Vaccines | |
| Wa1 |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | Hematological malignancies |
| disease | MESH | complications |
| disease | MESH | SARS-CoV-2 infections |
| disease | MESH | death |
| disease | MESH | multiple myeloma |
| disease | MESH | infections |
| disease | MESH | Infectious Diseases |
| disease | IDO | blood |
Original Article
(Visited 1 times, 1 visits today)